The scientists then tested three new mTOR inhibitors currently under development (pp242, AZD8055 and INK128) in combination
with the chemotherapies AraC,
Etoposide and Cisplatin to see how they affected laboratory lines of leukemia cells and mouse models of the disease.
High - Dose Chemotherapy Plus Transplant Not Recommended for DLBCL: The results of an Italian study report that treatment of high - risk diffuse large B - cell lymphoma (DLBCL)
with abbreviated course of rituximab dose - dense chemotherapy plus high - dose cytarabine, mitoxantrone, and dexamethasone (R - MAD) plus carmustine,
etoposide, cytarabine, and melphalan (BEAM) plus autologous stem cell transplantation compared
with a full course of rituximab dose - dense chemotherapy did not improve overall survival.